| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC22764 | CS-11 | A novel small molecule inhibitor that inhibits PP2A and β-catenin interaction by selectively engaging PR55α binding site (Kd=45 pM). |
|
| DC11822 | YD-277 | A novel small molecule KLF5 inhibitor derived from ML264, demonstrates >10-fold enhanced efficacy in multiple cancer cell lines with IC50 of 1.5-10 uM. |
|
| DC22879 | YK-3-237 | A novel small molecule sirtuin-1 (SIRT1) activator that reduces acetylation of mutant 53 and exhibits anti-proliferative effects against TNBC cells carrying mutant p53. |
|
| DC21330 | MM-206 | A novel small molecule STAT3 inhibitor that inhibits STAT3 DNA binding activity with IC50 of 1.16 uM, binds to the STAT3 coiled-coil domain (CCD). |
|
| DC11954 | JP-153 Featured | JP-153 (JP153) is a novel small molecule targets the Src-FAK-Paxillin signaling, inhibits Src-dependent phosphorylation of paxillin (Y118) and downstream activation of Akt (S473) in RECs; potently inhibits VEGF-induced proliferation and migration, inhibits retinal neovascularization in the murine oxygen-induced retinopathy model. |
|
| DC20389 | GATA4 activator 7 | A novel small molecule that activates GATA4/NKX2-5 transcriptional synergy with EC50 of 7 uM in cell reporter assay. . |
|
| DC21039 | GATA4-IN-3 Featured | A novel small molecule that inhibits GATA4/NKX2-5 transcriptional synergy with IC50 of 3 uM, with no activity on the protein kinases involved in the regulation of GATA4 phosphorylation. |
|
| DC11852 | CTX-1 | A novel small molecule that overcomes HdmX-mediated p53 repression, binds directly to HdmX (Kd=450 nM) to prevent p53-HdmX complex formation. |
|
| DC11669 | CB-002 Featured | CB-002 is a novel small molecule that restores p53 function in mutant p53-expressing colorectal cancer cells without toxicity to normal human fibroblasts; increases expression of endogenous p53 target genes NOXA, DR5, and p21 and cell death; decreases the stability of mutant p53 in RXF393 cancer cells and an exogenously expressed R175H p53 mutant in HCT116 p53-null cells. |
|
| DC21426 | NSC654259 | A novel small molecule Wnt signaling inhibitor that targets the cysteine-rich domain of Frizzled, specifically binds to the Wnt binding site on the Frizzled8 cysteine-rich domain with Kd of 2.9 uM, IC50 of 5.7 uM.. |
|
| DC11877 | F3406 | A novel small-molecule arenaviruse inhibitor that exhibits strong anti-LCMV activity (IC50<1 uM) without cell toxicity. |
|
| DC11908 | Ralaniten | A novel small-molecule inhibitor of androgen receptor (AR) N-terminal domain inhibitor for the treatment of advanced prostate cancer. |
|
| DC11909 | Ralaniten acetate | A novel small-molecule inhibitor of androgen receptor (AR) N-terminal domain inhibitor for the treatment of advanced prostate cancer. |
|
| DC20873 | CCT-031374 hydrobromide | A novel small-molecule Wnt signaling inhibitor that inhibits TCF-dependent transcription with IC50 of 6.1 uM in 7dF3 reporter assay. |
|
| DC21232 | Licogliflozin | A novel sodium glucose transporter type 1 and type 2 (SGLT1/2) inhibitor for the oral treatment of type 2 diabetes.. |
|
| DC23587 | AMG1 | A novel specific CRAC channel inhibitor that blocks function of effector but not regulatory T cells in vitro and attenuates the pogression and severity of EAE in vivo. |
|
| DC21056 | GMI-1271 Featured | A novel specific glycomimetic E-Selectin antagonist with Kd of 0.46 uM, IC50 of 1.75 uM. |
|
| DC11795 | BL-140 | A novel specific p110β inhibitor with IC50 of 5.74 nM. |
|
| DC22863 | FPND | A novel specific ROCK1 kinase inhibitor with IC50 of 11.2 uM, without inhibitory activity against ROCK2. |
|
| DC20372 | Elismetrep | A novel specific TRPM8 channel antagonist for treatment or prevention vasomotor symptoms.. |
|
| DC12000 | AUT2 | A novel specific, cell permeant modulator of Kv3 channels with EC50 of 0.9 and 1.9 uM for Kv3.1b and Kv3.2a, respectively. |
|
| DC5893 | SCD1 inhibitor Featured | A novel stearoyl-CoA desaturase1 (SCD1) inhibitor.The compound exhibited robust in vivo activity with dose-dependent desaturation index lowering effects. |
|
| DC22931 | 1Z105 | A novel synthetic, orally bioavailable TLR4/MD2 ligand, significantly reduces the IL-6 secretion by subsequent challenge with LPS at 0.63 uM. |
|
| DC23945 | Pyr10 Featured | Pyr10 is a pyrazole derivative and a selective TRP cation 3 (TRPC3) inhibitor. Pyr10 inhibits Ca2+ influx in carbachol-stimulated TRPC3-transfected HEK293 cells with an IC50 of 0.72 μM (IC50 of 13.08 μM for store operated Ca2+ entry in BRL-2H3 cells). Pyr10 has the ability to distinguish between receptor-operated TRPC3 and native stromal interaction molecule 1 (STIM1)/Orai1 channels[1]. |
|
| DC11694 | STK899704 | A novel tubulin inhibitor that inhibits the proliferation of cancer cell lines with IC50 of 0.2-1.0 uM. |
|
| DC21298 | Uprifosbuvir | A novel uridine nucleotide analog HCV NS5B polymerase inhibitor for treatment of HCV infection combined with Grazoprevir and Ruzasvir.. |
|
| DC10646 | VPS34 inhibitor(Compound 80) Featured | A novel VPS34 inhibitor. |
|
| DC11825 | MK-8876 | A novel, broadly acting non-nucleoside inhibitor of HCV NS5B polymerase with IC50 of 3 nM and 2 nM for GT1b and GT2a, respectively. |
|
| DC22790 | MELK-T1 hydrochloride | A novel, cell-permeable, potent and selective inhibitor of MELK kinase domain with IC50 of 37 nM. |
|
| DC23430 | THRX-200495 | A novel, dual-acting muscarinic receptor antagonist and β2-adrenoceptor agonist (MABA) with pKi of 9.21/9.53 for hM2/M3, pKi of 9.37 for β2-adrenoceptor. |
|
